Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Sanofi stories

Nov 13, 2026

Windward Bio prices $175M IPO to advance China-licensed lung drugs

Swiss immune drug developer Windward Bio raised $175 million in its IPO, the biotech sector's 30th listing of the year, to advance lung disease drugs licensed from China.

Nov 13, 2026·2 sources
00
Nov 12, 2026

FDA quietly shelves Trump's drug fast-track voucher program amid agency chaos

No new drugs have received a voucher under the FDA's fast-track review program since Marty Makary left the agency in May, with internal documents and sources indicating the program has been effectively abandoned amid ongoing agency turmoil.

Nov 12, 2026·2 sources
00
Nov 5, 2026

T-Therapeutics raises $133M Series B for cancer and autoimmune T cell receptor drugs

UK biotech T-Therapeutics has closed a $133 million Series B round backed by Johnson & Johnson, Merck KGaA, Eli Lilly, and Sanofi to advance T cell receptor therapies for cancer and autoimmune diseases into clinical development.

Nov 5, 2026·2 sources
00
Oct 29, 2026

Dren Bio raises $350 million for blood cancer drug ahead of potential 2027 launch

California biotech Dren Bio secured $350 million in funding to advance its lead blood cancer therapy toward a potential market launch by the end of 2027.

Oct 29, 2026·3 sources
00

ECDC report finds universal RSV immunization could significantly reduce infant hospitalizations in Europe

A new report from the European Centre for Disease Prevention and Control indicates that universal immunization of newborns against respiratory syncytial virus could significantly reduce infant hospitalizations across the EU. The findings come as the RSV season approaches, with evidence showing national programs using nirsevimab or maternal vaccination are associated with large reductions in infant hospitalizations.

Oct 29, 2026·2 sources
00
Oct 28, 2026

SAR402663 gene therapy shows 97% reduction in treatment burden for wet AMD in phase 2 trial

A phase 2 study presented in Vienna showed that SAR402663, a single intravitreal gene therapy injection for wet age-related macular degeneration, achieved a 97% reduction in treatment burden with positive efficacy and safety results. More than 90% of patients responded to the medium dose treatment.

Oct 28, 2026·2 sources
00
Oct 14, 2026

Sanofi avoids EU fine after settling antitrust probe over disparaging rival vaccine

The European Commission accepted Sanofi's commitments to end an antitrust investigation into allegations the company disparaged CSL Seqirus' competing flu vaccine. The commitments will become legally binding for Sanofi, allowing it to avoid a fine.

Oct 14, 2026·3 sources
00
Oct 1, 2026

Sanofi and Regeneron expand partnership in deal valued at up to $8 billion

Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in milestone payments to bring four new antibodies under their Dupixent partnership, expanding their immunology collaboration.

Oct 1, 2026·7 sources
00
Aug 27, 2026

AstraZeneca and Amgen's Tezspire meets Phase 3 goals in eosinophilic esophagitis

Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, potentially becoming the drug's third approved indication and positioning it to compete with Sanofi's Dupixent, currently the only approved biologic for the condition.

Aug 27, 2026·2 sources
00
Aug 12, 2026

Boulevard Bio launches with $65M to develop targeted autoimmune antibody therapies

Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.

Aug 12, 2026·4 sources
00
Jul 9, 2026

FDA Approves First Wearable On-Body Injector for Cancer Drug Delivery with Sanofi's Sarclisa

The FDA has approved Sanofi's Sarclisa (isatuximab) for subcutaneous delivery via a wearable on-body injector, marking the first cancer drug to receive approval for this delivery method. The device offers multiple myeloma patients a less burdensome alternative to intravenous infusions.

Jul 9, 2026·6 sources
00
Jun 26, 2026

European Commission Opens Antitrust Investigation Into Sanofi's Flu Vaccine Marketing Practices

The European Commission launched an antitrust probe into Sanofi for allegedly disparaging a rival's flu vaccine in its marketing campaigns, potentially violating competition rules.

Jun 26, 2026·3 sources
00
May 7, 2026

Sanofi Withdraws Diabetes Drug from FDA's Expedited Review Program After Political Interference

Sanofi requested the FDA remove its type 1 diabetes drug from Commissioner Marty Makary's new speedy drug review voucher program after a political appointee interfered with the review process.

May 7, 2026·1 source
00

Top claims

  • ▪Sanofi purchased $50 million of shares and pre-funded warrants in a private stock placement concurrent with Windward Bio's initial public offering
  • ▪Windward Bio begins trading on November 13, 2026 under the ticker symbol WWB
  • ▪Biopharmaceutical initial public offerings have raised over $8 billion in 2026, marking the sector's busiest IPO year since 2021

Topics

BiotechnologyAsthmaRespiratory diseasesPharmaceutical IndustryDrug developmentClinical trialsBiotech innovationCOPDDrug pricingDrug Policy, Pricing & ApprovalNovo NordiskAccelerated approval pathwaysGovernment and Regulatory PolicyFederal agenciesEli LillyTrump administrationFDA drug approvalCancer immunotherapyCancer & OncologyImmunotherapyVenture capital fundingBiotech startupAutoimmune disease treatmentsRare diseasesHematology & Blood CancersInfectious Disease and OutbreaksPublic healthChild healthVaccination programsVaccines and Immunization PolicyEpidemiologyDrug safetyIntravitrealWet AMDGene therapyAntitrust & competitionRegulatory enforcementBiologic therapiesDrug Approval and Clinical TrialsDigestive diseasesClinical evaluationClinical Trial Design & EvaluationPharmaAutoimmune diseaseDrug discoveryWearables & Health TrackingCancer treatment breakthroughsDrug Classes & Treatment AccessCancer Treatment & TherapiesEuropean UnionVaccine development and innovationFast track designationHealthcare Policy

Related entities

NasdaqSwitzerlandChinaGermanyUnited KingdomGeneral CatalystLightspeed Venture PartnersDenmarkSpainNetherlandsFinlandPoland